Free Trial

Viking Therapeutics (VKTX) Competitors

Viking Therapeutics logo
$30.19 +2.68 (+9.74%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$30.35 +0.16 (+0.52%)
As of 07/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VKTX vs. MDGL, LLY, QGEN, MRNA, VTRS, ASND, BPMC, BBIO, VRNA, and ROIV

Should you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), Qiagen (QGEN), Moderna (MRNA), Viatris (VTRS), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Roivant Sciences (ROIV). These companies are all part of the "medical" sector.

Viking Therapeutics vs. Its Competitors

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -123.38%. Viking Therapeutics' return on equity of -14.41% beat Madrigal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Madrigal Pharmaceuticals-123.38% -50.54% -37.19%
Viking Therapeutics N/A -14.41%-14.02%

In the previous week, Viking Therapeutics had 12 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 15 mentions for Viking Therapeutics and 3 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.98 beat Viking Therapeutics' score of 0.44 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Madrigal Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Viking Therapeutics
7 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Madrigal Pharmaceuticals currently has a consensus target price of $420.63, suggesting a potential upside of 46.29%. Viking Therapeutics has a consensus target price of $87.15, suggesting a potential upside of 188.68%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Madrigal Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89
Viking Therapeutics
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
3.00

Madrigal Pharmaceuticals has a beta of -1.05, indicating that its share price is 205% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.

Viking Therapeutics has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Viking Therapeutics is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Madrigal Pharmaceuticals$180.13M35.44-$465.89M-$18.05-15.93
Viking TherapeuticsN/AN/A-$109.96M-$1.15-26.25

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 21.5% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 4.1% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Viking Therapeutics beats Madrigal Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Viking Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VKTX vs. The Competition

MetricViking TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.09B$2.88B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.06%
P/E Ratio-26.2520.8027.0020.10
Price / SalesN/A286.98435.75120.29
Price / CashN/A41.1936.8257.86
Price / Book3.827.487.985.56
Net Income-$109.96M-$55.04M$3.16B$248.40M
7 Day Performance8.91%2.44%2.41%4.67%
1 Month Performance9.50%1.90%2.19%6.64%
1 Year Performance-44.25%4.35%33.82%21.31%

Viking Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VKTX
Viking Therapeutics
3.8522 of 5 stars
$30.19
+9.7%
$87.15
+188.7%
-40.8%$3.09BN/A-26.2520
MDGL
Madrigal Pharmaceuticals
4.0737 of 5 stars
$305.20
+1.5%
$420.63
+37.8%
-1.1%$6.78B$317.38M-16.9190
LLY
Eli Lilly and Company
4.9823 of 5 stars
$777.88
+0.3%
$1,011.61
+30.0%
-15.3%$737.23B$45.04B63.2947,000Trending News
Options Volume
QGEN
Qiagen
3.8827 of 5 stars
$48.08
+0.6%
$49.40
+2.7%
+22.3%$10.69B$1.98B120.555,765Dividend Announcement
MRNA
Moderna
4.3762 of 5 stars
$27.54
+1.4%
$46.61
+69.2%
-72.1%$10.65B$3.24B-3.155,800
VTRS
Viatris
2.6564 of 5 stars
$8.95
-0.7%
$10.40
+16.2%
-12.7%$10.50B$14.74B-2.8232,000
ASND
Ascendis Pharma A/S
3.5977 of 5 stars
$171.21
-0.6%
$220.67
+28.9%
+23.2%$10.47B$393.54M-27.261,017
BPMC
Blueprint Medicines
1.5043 of 5 stars
$128.15
+0.0%
$128.06
-0.1%
+10.4%$8.28B$562.12M-51.88640Insider Trade
BBIO
BridgeBio Pharma
4.6665 of 5 stars
$43.14
-3.8%
$58.85
+36.4%
+65.2%$8.19B$221.90M-12.22400
VRNA
Verona Pharma PLC American Depositary Share
2.6057 of 5 stars
$94.51
+0.7%
$101.10
+7.0%
+410.6%$8.05B$42.28M-47.2630Positive News
ROIV
Roivant Sciences
1.5177 of 5 stars
$11.28
-1.0%
$17.50
+55.1%
+1.3%$7.67B$29.05M-45.12860

Related Companies and Tools


This page (NASDAQ:VKTX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners